United States Patent Issued for CorMedix's Neutrolin(R) to Prevent Catheter Related Bloodstream Infections (CRBI) and Clotting in Hemodialysis Catheters

BRIDGEWATER, N.J.--(BUSINESS WIRE)--CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD.U), a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiorenal disease, today announced that the U.S. Patent and Trademark Office has issued a patent for the use of Neutrolin® for preventing infection and clotting in hemodialysis catheters. The invention further relates to an improved composition for maintaining patency of indwelling catheters involved in central blood access. U.S. Patent No. 7,696,182 was issued to ND Partners, LLC, and expires in 2025. CorMedix holds an exclusive worldwide license with ND Partners, LLC to develop Neutrolin® for the prevention of CRBI.

Back to news